申请人:Celltech Therapeutics Limited
公开号:US20020035092A1
公开(公告)日:2002-03-21
Propanoic acid derivatives of formula (1) are described:
Ar—X
1
—Ar
1
—Z—R (1)
in which
Ar is a nitrogen base containing group;
X
1
is linker atom or group;
Ar
1
is an optionally substituted 5- or 6-membered nitrogen-containing aromatic or non-aromatic monocycle;
Z is a group —CH(R
13
)CH
2
— [in which R
13
is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group], —C(R
12a
)(R
13
)—CH(R
12b
)— [in which R
12a
and R
12b
together with the carbon atoms to which they are attached form a C
3-7
cycloalkyl group] or C(R
13
)═CH—;
R is a carboxylic acid (—CO
2
H) or a derivative or biostere thereof; and the salts, solvates, hydrates and N-oxides thereof.
The compounds are able to inhibit the binding of &agr;
v
integrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders.
描述了化学式(1)的丙酸衍生物:
Ar-X1-Ar1-Z-R (1)
其中,Ar是含氮基团;X1是连接原子或基团;Ar1是可选地取代的含氮芳香或非芳香单环的5-或6-成员;Z是一个基团-CH(R13)CH2- [其中R13是可选的脂肪,环状脂肪,杂原子脂肪,杂环状脂肪,芳香或杂芳香基团],-C(R12a)(R13)-CH(R12b)- [其中R12a和R12b与它们所连接的碳原子共同形成C3-7环烷基团]或C(R13)HCH- ;R是羧酸(-CO2H)或其衍生物或生物立体异构体;以及它们的盐,溶剂合物,水合物和N-氧化物。这些化合物能够抑制αv整合素与其配体的结合,并可用于预防和治疗免疫或炎症性疾病。